Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

Core Viewpoint - Taysha Gene Therapies, Inc. (TSHA) is anticipated to report a year-over-year increase in earnings despite lower revenues, which could significantly influence its near-term stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.08 per share, reflecting a year-over-year change of +20% [3]. - Revenues are projected to be $2.1 million, representing a decline of 38.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.22% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with a strong predictive power for positive readings [7][8]. - Taysha Gene Therapies currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11]. Historical Performance - In the last reported quarter, Taysha Gene Therapies was expected to post a loss of $0.08 per share but actually reported a loss of $0.07, resulting in a surprise of +12.50% [12]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [13]. Conclusion - While Taysha Gene Therapies does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making investment decisions ahead of the earnings release [16].